Yvette Drew on Muck Rack

Yvette Drew

As seen in: British Journal of Cancer, Nature, JAMA Oncology
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Yvette

Contact Yvette, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Phase Ib trial of SL-172154, a bispecific CD47 inhibitor and CD40 agonist Fc-fusion protein, in combination with mirvetuximab soravtansine or pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer

|
By Yvette Drew, Lucy Gilbert, Alejandro Bueno, Ana Oaknin, Victor Moreno, Lydia Garcia, Gordon C Jayson, Rebecca S Kristeleit, Nehal Lakhani, Susana Banerjee, Daniela Matei, Amit M Oza, Rowan Miller, Dennis Yiannakis, Jerónimo García, Guanfang Wang, Debra Richardson, Maria-Pilar Barretina-Ginesta, Jayalakshmi Miriyala, Amy Franke, Elisa Galvez, Lini Pandite
| Nature
Abstract Platinum resistant ovarian cancer (PROC) is associated with poor survival. This clinical trial sought to determine whether the bispecific CD47 inhibitor and CD40 agonist, SL-172154, could be combined safely and improve the efficacy of mirvetuximab (MIRV) or pegylated liposomal doxorubicin (PLD) through enhanced tumor cell phagocytosis and antigen presentation to T cells.
Open in Who Shared Issue with article?

Clearing the Path for Immunologic Targeting of Gynecologic Clear Cell Carcinomas

|
By Yvette Drew
| JAMA Oncology
In this issue of JAMA Oncology, Gao and colleagues1 reported impressive results from a cohort of recurrent gynecologic clear cell cancers (rGCCCs) included in the phase 2 MoST-CIRCUIT prospective multicenter, rare cancers basket trial.
Open in Who Shared Issue with article?

First-in-human study of the PARP/tankyrase inhibitor E7449 in patients with advanced solid tumours and evaluation of a novel drug-response predictor

|
By Ruth Plummer, Nicola Cresti, Yvette Drew, Divyanshu Dua
| Nature
Abstract Background This phase 1 study examined the safety, maximum-tolerated dose (MTD) and antitumour activity of E7449, a novel PARP 1/2 and tankyrase 1/2 inhibitor. Methods E7449 was orally administered once daily in 28-day cycles to patients with advanced solid tumours (50–800-mg doses).
Open in Who Shared Issue with article?
See all 6 articles

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Get in touch with Yvette

Contact Yvette, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified